Irina Lehmann

Irina Lehmann

Auto-generated profile, based on publicly available information

Irina Lehmann

Berlin Institute of Health at Charité, Universitätsmedizin Berlin, Center of Digital Health, Molecular Epidemiology Unit, Berlin, Germany

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2020 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
RCRobert Lorenz Chua
Robert Lorenz Chua
SLSören Lukassen
Sören Lukassen
STSaskia Trump
Saskia Trump
BHBianca P. Hennig
Bianca P. Hennig
DWDaniel Wendisch
Daniel Wendisch
RERoland Eils
Roland Eils
To investigate the immune response and mechanisms associated with severe coronavirus disease 2019 (COVID-19), we performed single-cell RNA sequencing on nasopharyngeal and bronchial samples from 19 clinically well-characterized patients with moderate or critical disease and from five healthy controls. We identified airway epithelial cell types and states vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In patients with COVID-19, epithelial cells showed an average three-fold increase in expression of the SARS-CoV-2 entry receptor ACE2, which correlated with interferon signals by immune cells. Compared to moderate cases, critical cases exhibited stronger interactions between epithelial and immune cells, as indicated by ligand–receptor expression profiles, and activated immune cells, including inflammatory macrophages expressing CCL2, CCL3, CCL20, CXCL1, CXCL3, CXCL10, IL8, IL1B and TNF. The transcriptional differences in critical cases compared to moderate cases likely contribute to clinical observations of heightened inflammatory tissue damage, lung injury and respiratory failure. Our data suggest that pharmacologic inhibition of the CCR1 and/or CCR5 pathways might suppress immune hyperactivation in critical COVID-19.

18 August 2021 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
JLJ. Loske
J. Loske
JRJ. Röhmel
J. Röhmel
SLSören Lukassen
Sören Lukassen
SSS. Stricker
S. Stricker
VMV. G. Magalhães
V. G. Magalhães
ILI. Lehmann
I. Lehmann

24 December 2020 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
STSaskia Trump
Saskia Trump
SLSören Lukassen
Sören Lukassen
MAMarkus S. Anker
Markus S. Anker
RCRobert Lorenz Chua
Robert Lorenz Chua
JLJohannes Liebig
Johannes Liebig
ILIrina Lehmann
Irina Lehmann

11 February 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
BLBeate Leppert
Beate Leppert
SSSandra Strunz
Sandra Strunz
BSBettina Seiwert
Bettina Seiwert
LSLinda Schlittenbauer
Linda Schlittenbauer
RSRita Schlichting
Rita Schlichting
TPTobias Polte
Tobias Polte
Parabens are preservatives widely used in consumer products including cosmetics and food. Whether low-dose paraben exposure may cause adverse health effects has been discussed controversially in recent years. Here we investigate the effect of prenatal paraben exposure on childhood overweight by combining epidemiological data from a mother–child cohort with experimental approaches. Mothers reporting the use of paraben-containing cosmetic products have elevated urinary paraben concentrations. For butyl paraben (BuP) a positive association is observed to overweight within the first eight years of life with a stronger trend in girls. Consistently, maternal BuP exposure of mice induces a higher food intake and weight gain in female offspring. The effect is accompanied by an epigenetic modification in the neuronal Pro-opiomelanocortin (POMC) enhancer 1 leading to a reduced hypothalamic POMC expression. Here we report that maternal paraben exposure may contribute to childhood overweight development by altered POMC-mediated neuronal appetite regulation.

7 November 2017 in Allergy
Verified
Journal Article
Open access
PDF file
TKT. Keller
T. Keller
CHC. Hohmann
C. Hohmann
MSMarie Standl
Marie Standl
AWA. H. Wijga
A. H. Wijga
UGU. Gehring
U. Gehring
SRStephanie Roll
Stephanie Roll
Background: Cross‐sectional studies suggested that allergy prevalence in childhood is higher in boys compared to girls, but it remains unclear whether this inequality changes after puberty. We examined the sex‐specific prevalence of asthma and rhinitis as single and as multimorbid diseases before and after puberty onset in longitudinal cohort data.Methods: In six European population‐based birth cohorts of MeDALL, we assessed the outcomes: current rhinitis, current asthma, current allergic multimorbidity (ie, concurrent asthma and rhinitis), puberty status and allergic sensitization by specific serum antibodies (immunoglobulin E) against aero‐allergens. With generalized estimating equations, we analysed the effects of sex, age, puberty (yes/no) and possible confounders on the prevalence of asthma and rhinitis, and allergic multimorbidity in each cohort separately and performed individual participant data meta‐analysis.Findings: We included data from 19 013 participants from birth to age 14‐20 years. Current rhinitis only affected girls less often than boys before and after puberty onset: adjusted odds ratio for females vs males 0.79 (95%‐confidence interval 0.73‐0.86) and 0.86 (0.79‐0.94), respectively (sex‐puberty interaction P = .089). Similarly, for current asthma only, females were less often affected than boys both before and after puberty onset: 0.71, 0.63‐0.81 and 0.81, 0.64‐1.02, respectively (sex‐puberty interaction P = .327). The prevalence of allergic multimorbidity showed the strongest sex effect before puberty onset (female‐male‐OR 0.55, 0.46‐0.64) and a considerable shift towards a sex‐balanced prevalence after puberty onset (0.89, 0.74‐1.04); sex‐puberty interaction: P < .001.Interpretation: The male predominance in prevalence before puberty and the “sex‐shift” towards females after puberty onset were strongest in multimorbid patients who had asthma and rhinitis concurrently.

1 June 2024 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
JLJennifer Loske
Jennifer Loske
MVMirjam Völler
Mirjam Völler
SLSören Lukassen
Sören Lukassen
MSMirjam Stahl
Mirjam Stahl
LTLoreen Thürmann
Loreen Thürmann
STSaskia Trump
Saskia Trump
Rationale: Pharmacological improvement of cystic fibrosis transmembrane conductance regulator (CFTR) function with elexacaftor/tezacaftor/ivacaftor (ETI) provides unprecedented improvements in lung function and other clinical outcomes in patients with cystic fibrosis (CF). However, ETI effects on impaired mucosal homeostasis and host defense at the molecular and cellular levels in the airways of patients with CF remain unknown. Objectives: To investigate effects of ETI on the transcriptome of nasal epithelial and immune cells from children with CF at the single-cell level. Methods: Nasal swabs from 13 children with CF and at least one F508del allele aged 6 to 11 years were collected at baseline and 3 months after initiation of ETI, subjected to single-cell RNA sequencing, and compared with swabs from 12 age-matched healthy children. Measurements and Main Results: Proportions of CFTR-positive cells were decreased in epithelial basal, club, and goblet cells, but not in ionocytes, from children with CF at baseline and were restored by ETI therapy to nearly healthy levels. Single-cell transcriptomics revealed an impaired IFN signaling and reduced expression of major histocompatibility complex classes I and II encoding genes in epithelial cells of children with CF at baseline, which was partially restored by ETI. In addition, ETI therapy markedly reduced the inflammatory phenotype of immune cells, particularly of neutrophils and macrophages. Conclusions: Pharmacological improvement of CFTR function improves innate mucosal immunity and reduces immune cell inflammatory responses in the upper airways of children with CF at the single-cell level, highlighting the potential to restore epithelial homeostasis and host defense in CF airways by early initiation of ETI therapy.